Literature DB >> 12804646

2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia.

Panagiotis Tsirigotis1, Evangelos Venetis, Violeta Kapsimali, Dimitra Rontogianni, Ephrosini Varvitsioti, Vasiliki Pappa, Panos Apostolidis.   

Abstract

A 52-year-old woman presented to our clinic for investigation of agranulocytosis and mild lymphocytosis. A diagnosis of T-large granular lymphocyte leukemia was made, based on immunophenotyping findings of the peripheral blood lymphocytes (CD3, CD8, CD16, CD57). Flow cytometric analysis of TCR-Vbeta repertoire showed single Vbeta9 expression on peripheral T-cells. Clonality was also demonstrated with PCR analysis which revealed clonal rearrangement of TCRgamma-chain gene. Granulocyte-macrophage colony-stimulating factor (G-CSF) (G-CSF), cyclosporine, methylprednisolone and oral methotrexate failed to correct the neutropenia. Finally, treatment with 2-deoxycoformycin (DCF) was successful and resulted in complete correction of the neutrophil count. Flow cytometric analysis of TCR-Vbeta repertoire proved to be an effective method to assess the therapeutic response to various treatments and to evaluate residual disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804646     DOI: 10.1016/s0145-2126(03)00019-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.

Authors:  Renato Zambello; Gianpietro Semenzato
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

2.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

3.  T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?

Authors:  Johanna Schreiber; Alexander Pichler; Christoph Kornauth; Hannes Kaufmann; Philipp B Staber; Georg Hopfinger
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.